Insights

Home » Insights » Insights Intercept Blood System
Cerus 27/02/2020

Pathogen inactivation of blood components during outbreaks of infectious diseases in the European Union

The European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organized an expert consultation meeting (April 2019) to discuss the potential role of pathogen inactivation technologies (PI) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not...

Cerus 31/01/2020

First annual haemovigilance activity report released after universal implementation of INTERCEPT™ in France

Pathogen inactivation of platelet concentrates (PC) with the INTERCEPT Blood System has been universally implemented in metropolitan France from November 2017 onwards. Previously INTERCEPT had been deployed since 2006 in Alsace and in the French overseas departments.

Guidelines 30/10/2019

FDA Publishes New Guidance Document on Mitigating Bacterial Contamination in Platelet Components

The FDA’s final guidance document on mitigating bacterial contamination in platelet components, released on September 30, 2019, formally recognises the risk of transfusion-transmitted bacterial infections and the need for additional safety measures to protect patients.

Cerus 23/10/2019

First confirmed infections from West Nile virus in Germany

The West Nile virus (WNV) is an enveloped RNA virus, well-known since 1937. Originally from Africa, it has now reached temperate climate zones. The virus mainly infects birds, but can also be transmitted to humans by mosquitoes – or by contaminated blood products!

Cerus 30/08/2019

Transfusion of a false negative NAT HIV-infected blood donation does not lead to transmission in platelet recipients

In France, since 2010, the risk of HIV transmission by transfusion is reduced by the use of individual NAT.

Despite this testing approach, a false negative test result was obtained from a 57-year-old male repeat donor in March 2017, using the ProcleixUltrio assay. A repository sample from that donation tested positive with the Cobas Taqman HIV-1 (limit of detection at 95%, 17 copies/mL).